MSC1 Antibody

What is MSC-1 antibody and what is its primary target?

MSC-1 (AZD0171) is a first-in-class humanized IgG1 monoclonal antibody that binds with high affinity to leukemia inhibitory factor (LIF) . It functions as a potent and selective inhibitor of LIF, disrupting LIF signaling through the LIF receptor (LIFR), which leads to robust STAT3 inhibition . This antibody was developed to target the immunosuppressive tumor microenvironment (TME) and cancer stem cell populations in various solid tumors .

What is the biological rationale for targeting LIF in cancer?

LIF is a pleiotropic cytokine involved in multiple physiological and pathological processes. In cancer, LIF is highly expressed in subsets of tumors across multiple types and correlates with poor prognosis . The therapeutic rationale for targeting LIF stems from its dual role in: (1) promoting immunosuppression within the tumor microenvironment, particularly through its association with tumor-associated macrophages (TAMs), and (2) regulating cancer initiating cells (CICs), which contribute to tumor growth, metastasis, and therapy resistance . Research has established LIF as a promoter of cancer progression through its regulation of the tumor microenvironment and induction of self-renewal in tumor-initiating cells .

How does MSC-1 modify the tumor microenvironment?

MSC-1 modifies the tumor microenvironment through several key mechanisms:

• Conversion of immunosuppressive tumor-associated macrophages (TAMs) into immunostimulatory macrophages

• Decrease in the number of immunosuppressive M2 macrophages

• Increase in intratumoral natural killer (NK) cells

• Enhanced infiltration and activation of T cells within tumors

• Inhibition of STAT3 signaling pathways that contribute to immunosuppression

These effects collectively transform an immunosuppressive tumor environment into one that is more conducive to anti-tumor immune responses .

What phase of clinical development has MSC-1 reached?

MSC-1 has completed a phase I first-in-human study and is currently being evaluated in phase II clinical trials . The initial phase I study was an open-label, dose-escalation trial that assessed MSC-1 monotherapy in patients with advanced, unresectable solid tumors . Based on promising results from this trial, a phase II study investigating MSC-1 in combination with immunotherapy is now underway specifically in patients with metastatic pancreatic cancer .

What was the design of the phase I clinical trial for MSC-1?

The phase I clinical trial employed an accelerated-titration dose escalation followed by a 3+3 design . Key aspects of the trial design included:

• Intravenous administration of MSC-1 at doses ranging from 75-1500 mg every 3 weeks (Q3W)

• Treatment continued until disease progression or unmanageable toxicity

• Additional patients were enrolled in selected cohorts for further evaluation of safety, pharmacokinetics, and pharmacodynamics after dose escalation approval

• The primary objective was to characterize safety and determine the recommended phase II dose (RP2D)

• Secondary objectives included evaluation of antitumor activity, progression-free survival (PFS) by RECIST v1.1, pharmacokinetics, and immunogenicity

• Exploratory objectives focused on pharmacodynamic effects on circulating LIF and TME immune markers

This trial enrolled 41 patients across three centers: Vall d'Hebron University Hospital, Memorial Sloan Kettering Cancer Center, and Princess Margaret Cancer Center .

What is the recommended phase II dose (RP2D) for MSC-1 based on clinical trials?

The recommended phase II dose (RP2D) for MSC-1 was determined to be 1500 mg administered intravenously every 3 weeks (Q3W) . This dosing regimen was established in the phase I trial after evaluating multiple dose levels. Notably, the maximum tolerated dose was not reached during the trial, indicating a favorable safety profile even at the highest tested dose .

What preclinical models are most appropriate for studying MSC-1 efficacy?

Based on published research, the following preclinical models have proven effective for studying MSC-1:

• Syngeneic mouse tumor models for non-small cell lung cancer (NSCLC), ovarian cancer, and colon cancer have demonstrated reduced tumor growth with MSC-1 treatment

• Orthotopic glioblastoma multiforme (GBM) xenograft models have shown MSC-1's ability to decrease immunosuppressive M2 macrophages

• Human GBM organotypic tumor slices in ex vivo models for studying macrophage modulation

• Co-culture systems with monocytes and supernatants from GBM cell lines with LIF knockdown to study macrophage gene expression

• Combination therapy models using MSC-1 with checkpoint inhibitors (e.g., anti-PD1)

When designing experiments, researchers should consider models that allow for evaluation of both the immunomodulatory effects and direct anti-tumor activity of MSC-1.

What biomarkers should be assessed when evaluating MSC-1 activity in experimental settings?

Key biomarkers for assessing MSC-1 activity include:

• Circulating LIF levels to confirm target engagement

• STAT3 signaling pathways in tumor and immune cells

• M1:M2 macrophage population ratios within the tumor microenvironment

• CD8+ T-cell infiltration into tumors

• Changes in natural killer (NK) cell populations

• Activation status of infiltrating T cells

• LIF expression levels in tumor tissues

These biomarkers align with the hypothesized mechanism of action and provide insights into both pharmacodynamic effects and potential efficacy markers.

How should researchers evaluate combined MSC-1 and checkpoint inhibitor therapy in experimental models?

When designing experiments to evaluate MSC-1 in combination with checkpoint inhibitors, researchers should consider:

• Sequential vs. simultaneous administration protocols to determine optimal timing for synergistic effects

• Multiple checkpoint inhibitor options (anti-PD1, anti-PD-L1, anti-CTLA-4) to identify the most effective combinations

• Tumor models with varying baseline immunogenicity to assess efficacy across different tumor immune profiles

• Comprehensive immune profiling before, during, and after treatment to track dynamic changes in the tumor microenvironment

• Assessment of durable responses and development of immunological memory

• Evaluation of tumor growth, survival metrics, and immune cell infiltration patterns

• Analysis of macrophage polarization status as MSC-1 specifically targets TAM modulation

Preclinical data has already shown that combined MSC-1 with anti-PD1 achieves strong anti-tumor responses and durable disease-free survival in multiple tumor types in mouse models .

How does LIF expression correlate with response to MSC-1 therapy, and what methods are most reliable for LIF assessment?

LIF expression appears to be an important consideration for patient selection in clinical trials, with enrollment in expansion cohorts being restricted to patients with LIF-High expression using a diagnostic selection assay . While direct correlation data between LIF expression levels and response to MSC-1 is still emerging, the following methods are recommended for LIF assessment:

• Immunohistochemistry of tumor biopsies for protein-level expression

• RNA sequencing or qPCR for transcript-level evaluation

• Multiplex cytokine assays for measuring circulating LIF levels

• Single-cell sequencing for cellular source identification within the tumor microenvironment

• Digital spatial profiling to understand the spatial context of LIF expression in relation to immune cells

Current clinical trial designs incorporate LIF assessment as a stratification factor, suggesting its potential value as a predictive biomarker .

What mechanisms of resistance might develop against MSC-1 therapy, and how can they be studied?

Potential resistance mechanisms to MSC-1 therapy could include:

• Upregulation of alternative cytokines with overlapping functions to LIF

• Mutations in the LIF binding epitope recognized by MSC-1

• Activation of alternative signaling pathways that bypass LIF-LIFR-STAT3 axis

• Changes in tumor microenvironment composition that maintain immunosuppression despite LIF inhibition

• Development of neutralizing antibodies against the humanized MSC-1

To study these resistance mechanisms, researchers should consider:

• Long-term treatment models to enable resistance development

• Comparative transcriptomic and proteomic analysis of sensitive versus resistant tumors

• Single-cell analysis of tumor and immune populations before and after resistance emergence

• Functional assays to evaluate alternative pathways for macrophage polarization and cancer stem cell maintenance

• Generation of MSC-1-resistant cell lines for detailed molecular characterization

How can we optimize pharmacodynamic biomarker assessment in MSC-1 clinical studies?

Optimizing pharmacodynamic biomarker assessment for MSC-1 requires comprehensive planning:

• Collection timing: Obtain paired biopsies pre-treatment and at strategic on-treatment timepoints to capture dynamic changes in the tumor microenvironment

• Multi-parameter analysis: Employ multiplex immunohistochemistry, CyTOF, or single-cell sequencing to simultaneously evaluate multiple immune cell populations and activation states

• Blood-based biomarkers: Monitor circulating LIF levels, soluble immune checkpoint molecules, and cytokine profiles as less invasive surrogates

• Functional assays: Assess ex vivo functional capacity of immune cells isolated from patient samples

• Standardization: Implement rigorous standard operating procedures for sample collection, processing, and analysis to minimize technical variability

• Computational approaches: Develop integrated analysis of multiple biomarker datasets to identify patterns predictive of response

The phase I clinical trial already demonstrated on-treatment changes in circulating LIF and TME STAT3 signaling, M1:M2 macrophage populations, and CD8+ T-cell infiltration that were consistent with MSC-1's hypothesized mechanism of action .

Which tumor types are most likely to benefit from MSC-1 therapy based on current evidence?

Based on preclinical and early clinical evidence, several tumor types show promise for MSC-1 therapy:

• Pancreatic cancer: A phase II trial is currently evaluating MSC-1 in combination with immunotherapy for metastatic pancreatic cancer, and one pancreatic cancer patient in the phase I trial showed a 40% tumor reduction in one lesion despite having received four prior lines of therapy

• Non-small cell lung cancer (NSCLC): Demonstrated efficacy in mouse models and included as a specific expansion cohort in clinical trials

• Ovarian cancer: Showed positive responses in preclinical models and specified as an expansion cohort in clinical trials

• Glioblastoma multiforme (GBM): Preclinical data in orthotopic GBM xenograft models and organotypic tumor slices showed MSC-1's ability to decrease immunosuppressive M2 macrophages

• Colon cancer: Demonstrated efficacy in mouse models

These tumors typically exhibit immunosuppressive microenvironments with significant TAM involvement, aligning with MSC-1's mechanism of action.

How might MSC-1 be integrated into combination immunotherapy regimens?

Strategic approaches for integrating MSC-1 into combination immunotherapy regimens include:

• Sequencing approaches: MSC-1 pretreatment to remodel the tumor microenvironment followed by checkpoint inhibitors

• Rational combinations based on complementary mechanisms:

  • MSC-1 + anti-PD1/PD-L1 to simultaneously address macrophage polarization and T-cell exhaustion

  • MSC-1 + anti-CTLA-4 to address different aspects of immune priming and effector function

  • MSC-1 + chemotherapy to combine immunomodulation with direct cytotoxicity

• Biomarker-guided patient selection: Using LIF expression and TME characteristics to identify optimal candidates

• Schedule optimization: Determining ideal timing and dosing intervals for each agent in the combination

Preclinical data supports the combination of MSC-1 with checkpoint inhibitors, showing strong anti-tumor responses and durable disease-free survival in mouse models .

What novel methodologies could advance our understanding of MSC-1's effects on cancer stem cells?

Advanced methodologies to investigate MSC-1's effects on cancer stem cells include:

• Single-cell RNA sequencing to identify and characterize stem-like cell populations before and after MSC-1 treatment

• Lineage tracing experiments to monitor cancer stem cell fate following MSC-1 therapy

• Patient-derived organoid models to evaluate stem cell properties in a more physiologically relevant context

• CRISPR-based functional genomics to identify genetic dependencies that influence MSC-1 efficacy against cancer stem cells

• Multiplexed imaging to spatially map stem cell markers in relation to LIF expression and immune cell infiltration

• In vivo limiting dilution assays to quantitatively assess changes in cancer stem cell frequency following MSC-1 treatment

• Chromatin accessibility profiling (ATAC-seq) to examine epigenetic alterations in stem-like populations

These approaches could provide mechanistic insights into how LIF inhibition affects cancer stem cell maintenance, differentiation, and contribution to tumor progression.

What are the key technical challenges in developing and validating LIF detection assays for patient selection?

Developing reliable LIF detection assays for patient selection involves several technical challenges:

• Expression heterogeneity: LIF expression may vary across different regions of a tumor, requiring multiple sampling or larger tissue sections

• Threshold determination: Establishing clinically meaningful cutoffs for "LIF-High" status requires correlation with clinical outcomes

• Assay standardization: Ensuring consistent results across different laboratories and clinical sites

• Sample quality considerations: Optimizing preservation and processing methods to maintain LIF detectability

• Analytical validation: Demonstrating reproducibility, precision, and accuracy of the assay

Potential solutions include:

• Development of companion diagnostic assays with rigorous validation protocols

• Use of automated quantitative image analysis to reduce reader variability

• Implementation of quality control standards specific to LIF detection

• Multi-modal assessment combining protein, RNA, and functional readouts

• Centralized testing in clinical trials to maintain consistency

Current clinical trials are already employing diagnostic selection assays to identify patients with LIF-High expression .

What methodological approaches are most effective for studying MSC-1's effects on the tumor-immune microenvironment?

Effective methodological approaches for studying MSC-1's effects on the tumor-immune microenvironment include:

• Multiplex immunohistochemistry/immunofluorescence to visualize and quantify multiple immune cell populations simultaneously

• Single-cell technologies:

  • scRNA-seq for comprehensive immune cell phenotyping

  • CyTOF for high-dimensional protein-level characterization

  • Spatial transcriptomics to preserve tissue context

• Functional assays:

  • Ex vivo tumor slice cultures to assess immune cell activity

  • 3D co-culture systems with tumor cells and immune components

• In vivo models with intact immune systems (syngeneic models) rather than immunodeficient xenograft models

• Sequential biopsies in clinical studies to capture dynamic changes

• Computational approaches:

  • Deconvolution algorithms for bulk RNA-seq data

  • Spatial statistics for analyzing cell-cell interactions

These methods have already demonstrated MSC-1's ability to convert immunosuppressive TAMs into immunostimulatory macrophages and induce T-cell infiltration in tumors .

How can researchers distinguish direct effects of MSC-1 on cancer cells versus indirect effects mediated through immune modulation?

Distinguishing direct versus immune-mediated effects of MSC-1 requires careful experimental design:

• Comparative studies in immunodeficient versus immunocompetent models:

  • Testing MSC-1 in the same tumor model in both NOD/SCID mice (lacking adaptive immunity) and immunocompetent mice

  • Comparing efficacy differences to quantify immune contribution

• In vitro isolation experiments:

  • Direct treatment of cancer cell lines with MSC-1 in the absence of immune components

  • Assessment of proliferation, apoptosis, and stem cell properties

• Pathway-specific readouts:

  • Monitoring STAT3 activation in sorted tumor cells versus immune populations

  • Evaluating LIF receptor expression across different cell types

• Selective depletion studies:

  • Antibody-mediated depletion of specific immune cell populations (T cells, macrophages)

  • Assessment of MSC-1 efficacy with or without these populations

• Cell-specific genetic approaches:

  • Conditional knockout of LIF receptor in either tumor or specific immune cell populations

  • Evaluating differential responses to MSC-1

• Ex vivo studies using patient samples:

  • Treating tumor specimens with MSC-1 with or without autologous immune cells

These approaches can help delineate the relative contributions of direct anti-tumor effects versus immune-mediated mechanisms of MSC-1.